Spots Global Cancer Trial Database for chronic phase chronic myelogenous leukemia
Every month we try and update this database with for chronic phase chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | NCT03647215 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch... | 18 Years - | Incyte Corporation | ||
| Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor | NCT03907670 | Chronic Phase C... | 20 Years - 80 Years | Assiut University | ||
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | NCT00003056 | Leukemia Lymphoma Graft Versus Ho... | cyclosporine cyclosporine an... | 18 Years - 55 Years | Takeda | |
| Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI | NCT00363649 | Leukemia | GM-K562 cell va... Interferon alfa Sargramostim | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | NCT00004905 | Leukemia | filgrastim recombinant int... cyclophosphamid... cytarabine etoposide idarubicin peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia | NCT00004052 | Leukemia | QS21 bcr-abl peptide... | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00049192 | Chronic Myeloge... Chronic Phase C... Relapsing Chron... | oblimersen sodi... imatinib mesyla... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | NCT00100997 | Leukemia | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | NCT00006343 | Leukemia | recombinant int... cytarabine imatinib mesyla... | 18 Years - 70 Years | Novartis | |
| Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission | NCT00305708 | Congenital Ameg... Diamond-blackfa... Fanconi Anemia Leukemia Severe Congenit... Thrombocytopeni... | anti-thymocyte ... busulfan fludarabine pho... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera... | - 17 Years | University of California, San Francisco | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | NCT00003239 | Leukemia | Recombinant Int... Cytarabine Omacetaxine Mep... | 12 Years - | M.D. Anderson Cancer Center | |
| Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | NCT00093639 | Leukemia | everolimus imatinib mesyla... | 18 Years - | Novartis | |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | NCT01426334 | Accelerated Pha... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | dasatinib diagnostic labo... pharmacological... cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | NCT00015847 | Leukemia | recombinant int... imatinib mesyla... | 18 Years - | OHSU Knight Cancer Institute | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | NCT01227135 | Leukemia | hydroxychloroqu... imatinib mesyla... cytogenetic ana... polymerase chai... laboratory biom... pharmacological... | 18 Years - | University of Glasgow | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | NCT00006053 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | NCT04605211 | Myeloproliferat... Chronic Phase C... Chronic Myeloid... | Online Mindfuln... Internet-Based ... | 18 Years - | University of California, San Francisco | |
| Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | NCT00028847 | Leukemia | cytarabine imatinib mesyla... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia | NCT00004181 | Chronic Myelopr... Leukemia Multiple Myelom... | busulfan cyclophosphamid... allogeneic bone... radiation thera... | 15 Years - 55 Years | Northwestern University | |
| Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00045422 | Leukemia | recombinant int... imatinib mesyla... | - | Memorial Sloan Kettering Cancer Center | |
| BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | NCT00112775 | Leukemia | dasatinib imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia | NCT00005986 | Leukemia | busulfan cyclophosphamid... filgrastim recombinant int... in vitro-treate... peripheral bloo... radiation thera... | 18 Years - 65 Years | Masonic Cancer Center, University of Minnesota | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Natural History Study of Patients With Chronic Myelogenous Leukemia | NCT00429910 | Leukemia | 18 Years - 120 Years | Dana-Farber Cancer Institute | ||
| Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia | NCT00119340 | Leukemia | cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00101088 | Accelerated Pha... Blastic Phase C... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | imatinib mesyla... temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | NCT00002869 | Leukemia | recombinant int... cytarabine hydroxyurea | - | National Cancer Institute (NCI) | |
| Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | NCT00093639 | Leukemia | everolimus imatinib mesyla... | 18 Years - | Novartis | |
| Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | NCT00295971 | Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit... | anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra... | 1 Year - 17 Years | University of California, San Francisco | |
| Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00045422 | Leukemia | recombinant int... imatinib mesyla... | - | Memorial Sloan Kettering Cancer Center | |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | NCT00295880 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | umbilical cord ... | 12 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Bone Marrow Transplantation in Treating Patients With Leukemia | NCT00006451 | Graft Versus Ho... Leukemia Lymphoma | anti-thymocyte ... cyclophosphamid... cyclosporine methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | NCT00006343 | Leukemia | recombinant int... cytarabine imatinib mesyla... | 18 Years - 70 Years | Novartis | |
| Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | NCT00769327 | Leukemia | imatinib mesyla... nilotinib cytogenetic ana... fluorescence in... microarray anal... mutation analys... polymerase chai... polymorphism an... laboratory biom... | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia | NCT00004878 | Graft Versus Ho... Leukemia | therapeutic all... cytarabine fludarabine pho... idarubicin methotrexate tacrolimus in vitro-treate... peripheral bloo... | 50 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML | NCT00416884 | Leukemia | Campath Fludarabine Total Body Irra... T-Cell Deplete | 4 Years - 75 Years | OHSU Knight Cancer Institute | |
| Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI | NCT00363649 | Leukemia | GM-K562 cell va... Interferon alfa Sargramostim | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | NCT00006053 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | NCT00066326 | Leukemia | imatinib mesyla... tanespimycin | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | NCT00012376 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult... | bryostatin 1 sargramostim laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | NCT04838041 | Chronic Phase C... | Asciminib 40 MG Asciminib 40 MG... Asciminib 80 MG... Imatinib Nilotinib Dasatinib | 18 Years - | Medical College of Wisconsin | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT00003561 | Leukemia | recombinant int... sargramostim | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | NCT05007873 | Chronic Phase C... Philadelphia Ch... BCR-ABL1 Positi... BCR-ABL1 Positi... | Dasatinib Decitabine and ... | - | M.D. Anderson Cancer Center | |
| Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00345826 | Leukemia | dasatinib | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia | NCT00119340 | Leukemia | cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | NCT00301093 | Leukemia | GM-K562 cell va... imatinib mesyla... | 18 Years - | Dana-Farber Cancer Institute | |
| Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00030394 | Childhood Chron... Chronic Myeloge... Chronic Phase C... | imatinib mesyla... laboratory biom... pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission | NCT00233961 | Leukemia | filgrastim | 18 Years - | National Cancer Institute (NCI) | |
| BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | NCT00112775 | Leukemia | dasatinib imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT00055874 | Leukemia | recombinant int... cytarabine hydroxyurea imatinib mesyla... allogeneic bone... autologous bone... peripheral bloo... | 18 Years - 120 Years | Heidelberg University | |
| Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00022490 | Leukemia | cytarabine imatinib mesyla... | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | NCT04838041 | Chronic Phase C... | Asciminib 40 MG Asciminib 40 MG... Asciminib 80 MG... Imatinib Nilotinib Dasatinib | 18 Years - | Medical College of Wisconsin | |
| Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | NCT01227135 | Leukemia | hydroxychloroqu... imatinib mesyla... cytogenetic ana... polymerase chai... laboratory biom... pharmacological... | 18 Years - | University of Glasgow | |
| Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment | NCT00072579 | Leukemia | sargramostim | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia | NCT00002789 | Leukemia | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | 15 Years - 65 Years | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
